This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Topical treatment for fungal nail disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Topical drugs in fungal nail disease

  • antifungal drugs can be:
    • fungistatic
      • preventing further growth of fungal cells, or
    • fungicidal
      • killing fungal cells entirely

Recommendations when to use topical therapy as monotherapy (1):

  • role of monotherapy with topical antifungals is limited to Superficial White Onychomycosis (SWO) (except in transverse or striate infections),
  • early Distal and Lateral Subungal Onychomycosis (DLSO) (except in the presence of longitudinal streaks) when < 80% of the nail plate is affected with lack of involvement of the lunula,
  • or when systemic antifungals are contraindicated

Topical drugs are usually applied daily for 12 months in order to allow the normal nail to grow and replace the regions damaged by infection:

  • drugs formulated for topical application in onychomycosis include:
    • allylamine (e.g. butenafine, terbinafine),
    • azole (e.g. clotrimazole, efinaconazole, miconazole),
    • hydroxypyridone (e.g. ciclopirox),
    • morpholine-derivative (e.g. amorolfine, Kunzea oil) - 5% amorolfine nail lacquer used once or twice a week 6 months for fingernails and 12 months for toe nails is recommended by PHE (2)
    • benzoxaborole (e.g. tavaborole) classes
  • azoles, allylamines, and morpholine-derivative drugs
    • inhibit ergosterol biosynthesis, an essential component of the cell wall
  • hydroxypyridone-class drug ciclopirox
    • inhibits metalloproteases by binding metal ions (metalloproteases are enzymes that help with fungal cell survival)
  • benzoxaborole-class drugs
    • inhibit protein translation by inhibiting the fungal leucine transfer ribonucleic acid (tRNA) synthetase
  • application of topical treatments is usually daily for 12 months, with amorolfine applied once or twice weekly for 12 months

  • topical treatments come in cream, lacquer, and solutions of varying concentrations (e.g. 5% to 10%) and are applied to the nail plate and skin surrounding the nail
    • in lacquers, alcohol solution is used to remove buildup of lacquer on the nails
    • topical treatments do not generally have drug interactions, which is useful where patients are already taking multiple oral medications
    • adverse events are usually related to skin reactions around the nail, such as rash, itching, or burning
    • a 40% urea ointment is available for the treatment of onychomycosis
      • urea ingredient provides non-surgical nail ablation of onychomycosis

  • a systematic review concluded that (5):
    • there is
      • high-quality evidence that efinaconazole 10% solution is more effective in achieving complete cure
      • low-quality evidence that ciclopirox 8% lacquer may better lead to complete cure
      • moderate-quality evidence in support of tavaborole 5% solution and P-3051 (ciclopirox 8% hydrolacquer) probably being more likely to achieve complete cure
        • although for P-3051 the comparators are ciclopirox 8% lacquer or amorolfine 5%, rather than vehicle
      • not all patients can be expected to achieve complete cure, since reported cure rates in clinical studies, while better than vehicle, are still low

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.